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1. Introduction 
The potentiating effects of methylxanthines on 
insulin release in response to glucose and other agents 
have been attributed to an increase in the P-cell con- 
centration of cyclic 3’,5’-Ah4P following inhibition 
of cyclic 3’,5’-AMP-phosphodiesterase (EC 3.1.4.~) 
[ 1,2] ; conversely the inhibition of glucagon-stimu- 
lated insulin release by imidazole has been ascribed 
to a stimulation of the &cell phosphodiesterase [l] . 
However, very little is known about cyclic 3’,5’- 
nucleotide phosphodiesterase in this tissue; although 
extracts of normal mouse islets have been shown to 
catalyse the breakdown of radioactive cyclic 3’,5’- 
AMP [3] there are no data on the kinetics of the 
enzyme(s) responsible. Some kinetic information 
has been presented for the phosphodiesterase activ- 
ity in a hamster islet carcinoma [41 but it is not 
known whether such results are typical of the normal 
P-cell. In the present study we describe a new sensi- 
tive assay for phosphodiesterase activity and report 
evidence that suggests that normal mouse islets of 
Langerhans contain at least two forms of cyclic nu- 
cleotide phosphodiesterase, with widely different 
Km’s for cyclic 3’,5’-AMP. Data are also given on the 
sensitivity of the low Km phosphodiesterase towards 
some agents that might affect insulin release through 
modulation of phosphodiesterase activity. 
* To whom to address correspondence. 
** Present address: Dept. of Histology, University of UmeP, 
Sweden. 
2. Methods 
Islets were isolated by a collagenase method [5] from 
the pancreata of 3-4 week-old male white mice. Islet 
extracts were prepared by sonication (5-10 set at 
position 2 on a Soniprobe, Dawe Instruments) of 
150-200 islets in 200 ~1 of cold 0.1 M triethanolamine, 
10 mM MgS04, 0.5 mM EDTA, pH 7.7. The soni- 
cate was dialysed for l-3 hr at 4” against 500 ml of 
the same buffer and then frozen. The frozen extracts 
were stored at -20” until used (within 4 days). 
For assay of cyclic nucleotide phosphodiesterase 
activity, the islet extracts were diluted with buffer to 
a concentration equivalent to about 0.4 islets/pi. 
10 ~1 of the diluted extract were incubated at 37’ 
with 50 ~.tl buffer containing MgSO, and EDTA as 
above and cyclic 3’,5’-AMP as required. Other addi- 
tions are as described in the tables and figures. After 
60 min the reaction was stopped by heating the 
reaction tubes at 80” for 4 min. The 5’-AMP formed 
was then converted to ATP by adding 20 yl of buffer 
containing 3 mg/ml phosphoenolpyruvate, 15 units/ 
ml pyruvate kinase and 18 units/ml myokinase. The 
ATP formed was finally assayed photokinetically by 
a luciferin-luciferase method [6]. Tissue and me- 
dium blanks were carried through the whole proce- 
dure. The concentration of ATP in standards as well 
as that of cyclic 3’,5’-AMP in the reaction medium 
was spectrophotometrically determined (AZ6c) in 
each experiment. 
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Table 1 
Recovery of S’AMP as ATP. 
5’-AMP added 
(pmole) 
5’-AMP recovered as ATP 
Enzyme absent Enzyme present 
(t-mole) (pmole) 
13.9 15.8 ? 2.3 (114%) 13.8 i 1.5 (99%) 
27.8 27.4 f 1.2 (99%) 26.3 f 2.1 (95%) 
Islet extract (enzyme present) or buffer (enzyme absent) 
was incubated for 60 min at 37” with the listed amounts of 
5’AMP. Recoveries of 5’-AMP as ATP are given as mean 
values + S.E. for 8 observations representing duplicate de- 
terminations of 4 different incubates. The islet extract used 
split 3’,5’-AMP at a rate of 6.7 pmole/islet per hr at 2.4 PM 
cyclic 3’,5’-AMP and at a rate of 9.2 pmole/islet per hr at 
19.3 rM cyclic 3’,5’-AMP. These enzyme activities corre- 
sond to a total production of 36.2 and 50.2 pmole of 
5’-AMP. 
3. Results 
The assay that we have used for the measurement 
of islet phosphodiesterase activity is based in prin- 
ciple on a method described [7] for assay of cyclic 
3’,5’-AMP. Control experiments showed that the 
rate of formation of 5’-AMP from cyclic 3’,5’-AMP 
was constant for at least 1 hr under the conditions 
used and was linearly related to the concentration 
of islet extract added: the extent of breakdown of 
cyclic 3’,5’-AMP was less than 10% of the amount 
initially present. It was particularly important to 
verify that the islet extract did not catalyse signifi- 
cant loss of 5’-AMP [3,8]. Table 1 shows that the 
mouse islet extracts did not significantly degrade 
5’-AMP at concentrations similar to those arising 
from phosphodiesterase activity. The data given in 
table 1 also demonstrate that there was a quantita- 
tive conversion of 5’-AMP to ATP in the second 
stage of the assay procedure. 
Rates of hydrolysis (v) of varying concentrations 
of cyclic 3’,5’-AMP (S) are shown in fig. 1 plotted 
in the form v against v/S. Such plots were curvilinear 
suggesting the presence in the extracts of two forms 
of phosphodiesterase with different K, -values for 
cyclic 3’,5’-AMP. Estimates of the apparent K, 
derived from four such plots yielded mean values 
of 10 and 500 PM: mean values of V,, for the two 
phosphodiesterase activities were 11 and 39 pmole/ 
islet/hr equivalent to 0.37 and 1.33 Ctmole/min/g 
dry islet, assuming a mean islet weight of 0.5 ccg [9]. 
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Fig. 1. Dependence of cyclic nucleotide phosphodiesterase 
activity (pmole of 3’,5’-AMP split/islet per hr) on cyclic 
3’,5’-AMP concentration. The intercepts of the straight lines 
with the ordinate and the abscissa were used to estimate 
kinetic parameters, assuming the presence of two enzymes. 
K ,,,i = 3.51rM; VmnX1 
0.5 mM; Vm,.. 
= 9.5 pmole/islet per hr; Km? = 
= 5 3 pmole/islet per hr. 
Over the range of cyclic 3’,5’-AMP concentrations 
from 1 to 25 PM the low K, activity is the predomi- 
nant contributor to the reaction rate. The effect of 
caffeine (5.3 mM) on the low K, activity is shown 
in fig. 2. Caffeine was a competitive inhibitor with an 
apparent Ki of 1 mM. 
The effects of some other agents on the phospho- 
diesterase activity at a cyclic 3’,5’-AMP concentra- 
tion of 2 PM are shown in table 2. Glucose (16.5 .mM), 
arginine (9 mM) and CaC& (1.7 mM) had no signi- 
ficant effects (P > 0.01). 3-Isobutyl-l-methylxan- 
thine was an extremely potent inhibitor of mouse 
islet phosphodiesterase activity, producing 89% in- 
hibition at a concentration of 0.8 mM. Phosphodi- 
esterase activity was also inhibited by glibenclamide 
(8.7 pg/ml) and by cyclic 3’,5’-GMP (8 PM). Imida- 
zole (2.6 mM) significantly stimulated phosphodi- 
esterase activity. 
4. Discussion 
The probable importance of cyclic 3’,5’-AMP in 
potentiating effects of glucose and other secretagogues 
on insulin release suggests the need for information on 
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Fig. 2. Inhibition of cyclic nucleotide phosphodiesterase 
activity (pmole of 3’,5’-AMP split/islet per hr) by caffeine 
((e-e-e): zero; (o-o-o): 5.3 mM) at low cyclic 3’,5’-AMP 
concentrations. Results are plotted in double-reciprocal form. 
the enzymes involved in the formation and break- 
down of this nucleotide in the P-cell. In the present 
study of cyclic 3’,5’-AMP phosphodiesterase, the 
problem of assaying the kinetics of this activity in 
the small amounts of islet tissue isolable by current 
methods (< 1 mg wet tissue) has been overcome 
by the development of a sensitive assay for phospho- 
diesterase. A limitation of our results arises from the 
fact that mouse islets contain cell-types in addition 
to the &cells; however the B-cells account for 80% 
of the mouse islet cells [lo] and it seems reasonable 
to assume that the activity that we study is charac- 
teristic of the P-cell. Subject to this reservation, the 
properties of the islet phosphodiesterase show si- 
milarities to the properties of this activity described 
in other mammalian tissues. Thus inhibition of cyclic 
3’,5’-AMP hydrolysis by cyclic 3’,5’-GMP has been 
observed for a low K, phosphodiesterase prepared 
from thymic lymphocytes [ 111 and also for a puri- 
fied phosphodiesterase prepared from rabbit skeletal 
muscle [ 121 . A stimulation of brain phosphodiester- 
ase by imidazole has also been reported [ 131. 
Of most significance for the problem of the control 
Table 2 
Effects of various compounds on cyclic nucleotide 
phosphodiesterase activity. 
Compound Cyclic 3’,5’-AMP Change 
split/islet per hr (%) 
(pmole) 
None (control) 2.41 i 0.07 - 
CaCla, 1.7 mM 2.16 f 0.05 -10 
Glucose, 16.5 mM 2.36 * 0.05 -2 
Arginine, 9.1 mM 2.51 i 0.06 +4 
Cyclic 3’,5’GMP, 7.9 PM 1.28 f 0.05 -47*** 
3-Isobutyl-l-methyl- 
xanthine, 0.8 mM 0.26 i 0.08 -ag*** 
Glibenclamide, 8.7 rg/ml 1.93 f 0.04 _20*** 
Imidazole, 26 mM 2.79 i (LO8. +16** 
All tubes contained 2.0 rM cyclic 3’,5’-AMP and enzyme ex- 
tract corresponding to 5.5 islets. Results are given as mean 
values f SE. for 8 observations representing duplicate de- 
terminations of 4 different incubates. 
** P < 0.01 
***p<o.o01 
of insulin release are the effects of glibenclamide and 
methylxanthines. Inhibition of phosphodiesterase by 
sulfonylureas has previously been observed in prep- 
arations of phosphodiesterase from kidney and pan- 
creas [14] and from an islet cell tumour from the 
hamster [4] . In the present study, glibenclamide was 
also found to inhibit phosphodiesterase activity in 
normal mouse islets. The question arises whether 
this effect may provide a basis for the insulin-secretory 
activity of the sulfonylureas. There are no published 
data on the effect of sulfonylureas on the concentra- 
tion of cyclic 3’,5’-AMP in islets and therefore direct 
evidence for this hypothesis is lacking. One objec- 
tion to such a mechanism is the recent demonstra- 
tion that sulfonylureas do not readily penetrate into 
the islet-cells of obese-hyperglycemic mice [ 151 
suggesting that their locus of action may be the fl- 
cell membrane; the intracellular localisation of phos- 
phodiesterase in islets is not known. 
Caffeine, which potentiates effects of glucose on 
insulin release from mouse islets [ 161 and elevates 
islet cyclic 3’,5’-AMP concentration [2, 171 was 
found to be a competitive inhibitor of the low K, 
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phosphodiesterase in islets with an apparent Kj of 
1 mM. This result is consistent with the effect of 
caffeine on insulin release being mediated by cyclic 
3’,5’-AMP, although additional or alternative modes 
of action can not be excluded. 3-Isobutyl-ethyl- 
xanthine was a more potent inhibitor of phospho- 
diesterase than was caffeine; this finding may ex- 
plain the relative efficiency of these agents in ele- 
vating cyclic 3’,5’-AMP concentration in rat [2] or 
mouse [17] islets. 
Kinetic analysis of the cyclic 3’,5’-AMP phospho- 
diesterase suggests the presence in mouse islets, as 
in a number of other mammalian tissues [ 18-201, of 
two forms of phosphodiesterase with widely different 
K, values for cyclic 3’,5’-AMP. Since in mouse 
islets the concentration of cyclic 3’,5’-AMP is approxi- 
mately 0.5 PM [14] , the low K, phosphodiesterase 
may be of most significance for the physiological 
regulation of islet cyclic 3’,5’-AMP concentration. 
Further characterisation of these activities may re- 
quire separation and purification. 
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